Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511862 · ClinicalTrials.gov registry record · Phase 2
TheraSphere for the Treatment of Liver Metastases
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT00511862 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 151 participants.
The verdict
NCT00511862, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-directed therapies.
Interventions
- DEVICE Yttrium 90 glass microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511862
The ClinicalTrials.gov registry entry for NCT00511862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Yttrium 90 glass microspheres is the first listed.
NCT00511862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511862 about?
NCT00511862 is a clinical study titled "TheraSphere for the Treatment of Liver Metastases". This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be treated or is progressing following treatment with systemic or other liver-...
What is the current status of trial NCT00511862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2007-01. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00511862?
The interventions under investigation include: Yttrium 90 glass microspheres (DEVICE).
Who is sponsoring clinical trial NCT00511862?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.